Company intelligence / Profile preview

AmDerma Pharmaceuticals

Bridgewater, New Jersey, United Statesamneal.com ↗

Ownership: Private
Development stage: Other

Overview

AmDerma Pharmaceuticals was a U.S. pharma company focused on dermatology and specialty topical products. It developed and commercialized drugs for skin and wound care, including FDA-approved econazole nitrate foam for tinea pedis, and licensed rights to Microcyn-based products for acne and atopic dermatitis. Its most advanced unapproved candidate, potassium dobesilate, reached Phase 2 for psoriasis. The company appears inactive as of 2025, though some of its products may remain on the market.

Therapeutic areas: Infectious DiseasesDermatology
Modalities: Small moleculeTopical formulationDermal delivery systemHydrogel-based drug delivery therapy
Industry: Biotech

Drug pipeline

2 assets

AM001

Unknown

1 more asset in the full pipeline.

Partnerships

Oculus Innovative Sciences (Microcyn Technology license)

Beyond the preview

Go deeper on AmDerma Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AmDerma Pharmaceuticals.